Trials / Completed
CompletedNCT01312636
Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency
A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Congenital FVII Deficiency - Registry for All Treated Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Japan. The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | activated recombinant human factor VII | Data will be collected at the baseline visit and approximately once a year until end of study. |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2011-03-11
- Last updated
- 2014-10-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01312636. Inclusion in this directory is not an endorsement.